New Drug Development for Known and Emerging Viruses
CHF 386.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Holenz, Jörg (Reihe Hrsg.) / Buschmann, Helmut (Hrsg.) / Rübsamen-Schaeff, Helga (Hrsg.)
- ISBN: 978-3-527-81071-0
- EAN: 9783527810710
- Produktnummer: 38056340
- Verlag: Wiley-Vch
- Sprache: Englisch
- Erscheinungsjahr: 2021
- Seitenangabe: 528 S.
- Plattform: PDF
- Masse: 11'207 KB
Über den Autor
Helga Rubsamen-Schaeff , PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rubsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market. Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.
100 weitere Werke von Raimund (Reihe Hrsg.) Mannhold:
Bewertungen
Anmelden